Get the Stockscreener App
0.00
100.00%
-3.18
Esperion Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
See More
Previous Close:
$3.18
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$819.46M
Revenue:
$418.24M
Net Income/Loss:
$-7.42M
P/E Ratio:
0.00
EPS:
-0.1034
Net Cash Flow:
$-10.88M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$4.175
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
0.00 | 819.46M | 418.24M | -7.42M | -10.88M | -0.1034 |
TAK
Takeda Pharmaceutical Co Adr
|
17.15 | 53.43B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.10 | 44.52B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.03 | 37.52B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.56 | 32.24B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
535.67 | 22.46B | 3.17B | 1.29B | 1.01B | 27.09 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Piper Sandler | Overweight |
| Dec-18-24 | Initiated | Goldman | Neutral |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
Esperion Therapeutics (ESPR) Stock Forecast & Analyst Ratings - Moomoo
Why Did ESPR Stock Surge 58% In Pre-Market Today? - Stocktwits
ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts - Stocktwits
[EFFECT] Esperion Therapeutics, Inc. SEC Filing - Stock Titan
Esperion Therapeutics, Inc. SEC Filing (Jul 16, 2026) - Stock Titan
PFE6265887 Bond Coupon Profile — Rate & Payments - TradingView
Wasatch Advisors reports 0.7% Esperion Therapeutics (ESPR) stake - Stock Titan
BioPharma Credit, Affiliate Lend $400 Million to Archimed for Esperion Therapeutics Deal - Moomoo
Enterprise value to revenue forward of Esperion Therapeutics, Inc. – DUS:0ET - TradingView
Key facts: Esperion to Delist from Nasdaq; Merger Creates $100M CVR - TradingView
REGBioPharma Credit PLCUPDATE ON ARCHIMED ESPERION ACQUISITION - TradingView
PFE6265887 Bond Risk Profile - TradingView
Esperion Therapeutics, Inc.(NasdaqGM: ESPR) dropped from S&P Global BMI Index - marketscreener.com
Esperion Therapeutics, Inc.(NasdaqGM: ESPR) dropped from S&P TMI Index - marketscreener.com
Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
Form 4 Esperion Therapeutics Inc For: 13 July By Investing.com - Investing.com Nigeria
PFE6265887 Bond Profile — Key Metrics - TradingView
Esperion Therapeutics (ESPR) director equity cashed out at $3.16 plus CVRs - Stock Titan
Esperion Therapeutics (ESPR) director exits equity as merger pays $3.16 plus CVRs - Stock Titan
Esperion Therapeutics (ESPR) director converts shares and options into $3.16 cash and CVRs - Stock Titan
Esperion Therapeutics (ESPR) director equity cashed out at $3.16 plus CVRs in merger - Stock Titan
Esperion Therapeutics (ESPR) director exits holdings in $3.16-per-share cash and CVR merger - Stock Titan
Esperion Therapeutics (ESPR) CCO swaps 424,536 RSUs for $3.16 cash plus CVRs - Stock Titan
Esperion Therapeutics (ESPR) CLO equity cashed out at $3.16 plus CVRs - Stock Titan
[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity - Stock Titan
Esperion Therapeutics (ESPR) CEO exits equity in cash-and-CVR merger payout - Stock Titan
An unknown funds, managed by ArchiMed SAS completed the acquisition of Esperion Therapeutics, Inc. from Wasatch Advisors LP, BlackRock, Inc. and others. - marketscreener.com
[POSASR] Esperion Therapeutics, Inc. SEC Filing - Stock Titan
Esperion Therapeutics, Inc. SEC Filing (Jul 13, 2026) - Stock Titan
Esperion Therapeutics, Inc. Announces Board Changes - marketscreener.com
Esperion Therapeutics Acquired by Essence Parent Inc.: Merger, NASDAQ Delisting, and Contingent Value Rights Details – Minichart - Minichart
Esperion Therapeutics (ESPR) moves to remove its Nasdaq listing - Stock Titan
Esperion Therapeutics Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Esperion Therapeutics, Inc.(NasdaqGM: ESPR) dropped from NASDAQ Composite Index - marketscreener.com
Esperion Therapeutics, Inc. (ESPR) Latest Stock News & Headlines - Yahoo Finance
Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger - Yahoo Finance
ESPR Stock Price, Quote & Chart - ChartMill
Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Esperion Therapeutics Stockholders Approve Merger with Essence Parent Inc. – Key SEC 8-K Filing Details - Minichart
Esperion Therapeutics (ESPR) investors back merger with Essence Parent in special meeting vote - Stock Titan
Esperion Therapeutics stock leans on its cholesterol portfolio. - ad-hoc-news.de
Esperion Therapeutics (ESPR) AGM 2026 Summary - Quartr
ESPREsperion Therapeutics Inc Volatility & Greeks - Finviz
Esperion Therapeutics focuses on cholesterol treatments as investors watch long-term growth - AD HOC NEWS
10 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga
ESPR News | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill
Esperion Therapeutics(ESPR) Stock Options Chain | Quotes & News - Moomoo
Esperion Therapeutics Company Profile & Introduction - Moomoo
Enterprise value to revenue forward of Esperion Therapeutics, Inc. – NASDAQ:ESPR - TradingView
Price to earnings forward of Esperion Therapeutics, Inc. – NASDAQ:ESPR - TradingView
Esperion Therapeutics, Inc. Actuals & Estimates (NASDAQ:ESPR) - TradingView
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Esperion Therapeutics Inc Stock (ESPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Koenig Sheldon L. | President and CEO |
Jun 17 '26 |
Sale |
3.15 |
53,588 |
169,070 |
2,119,111 |
| Halladay Benjamin | Chief Financial Officer |
Jun 17 '26 |
Sale |
3.15 |
10,773 |
33,989 |
702,829 |
1.50%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):